CervoMed Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CRVO research report →
Companywww.cervomed.com
CervoMed Inc. , a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery.
- CEO
- John J. Alam
- IPO
- 2008
- Employees
- 15
- HQ
- Boston, MA, US
Price Chart
Valuation
- Market Cap
- $30.00M
- P/E
- -1.00
- P/S
- 93.00
- P/B
- 2.83
- EV/EBITDA
- -0.72
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -9642.13%
- Net Margin
- -9311.65%
- ROE
- -136.08%
- ROIC
- -242.22%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,966,367 · -65.53%
- EPS
- $-2.98 · -47.52%
- Op Income
- $-28,294,877
- FCF YoY
- -41.86%
Performance & Tape
- 52W High
- $13.13
- 52W Low
- $2.82
- 50D MA
- $3.92
- 200D MA
- $6.70
- Beta
- -0.64
- Avg Volume
- 69.82K
Get TickerSpark's AI analysis on CRVO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 11, 26 | Winton Matthew | other | 30,000 |
| Feb 11, 26 | Gregoire Sylvie | other | 75,000 |
| Feb 11, 26 | ELDER WILLIAM ROBERT | other | 30,000 |
| Feb 11, 26 | De Rosch Mark | other | 30,000 |
| Feb 11, 26 | Blackburn Kelly | other | 30,000 |
| Feb 11, 26 | ALAM JOHN J | other | 75,000 |
| Oct 27, 25 | Quigley David | other | 16,200 |
| Oct 27, 25 | Quigley David | other | 0 |
| Nov 18, 25 | Winton Matthew | buy | 1,500 |
| Nov 17, 25 | Winton Matthew | buy | 3,500 |
Our CRVO Coverage
We haven't published any research on CRVO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CRVO Report →